VIENNA — Additional results from a late-stage trial studying Eli Lilly's closely-watched GLP-1 pill orforglipron further underscore its lackluster performance when lined up against the oral form of Novo Nordisk’s Wegovy.
In the Phase 3 ATTAIN ...
↧
#EASD25: Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo's oral Wegovy
↧